The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal
Walmart, AbbVie, Nike, Uber and PayPal are included in this Analyst Blog....…
173,830€
0,28%
Echtzeit-Aktienkurs ABBVIE
Bid:
Ask:
Nachrichten zur ABBVIE Aktie
Top Analyst Reports for Walmart, AbbVie & Nike
Todays Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike,…
AbbVie slips as Cigna adds more Humira biosimilars for coverage
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Dividend Roundup: Unilever, PNC Financial, Oracle, AbbVie, and more
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie updates full-year EPS estimate range; below consensus
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
UPDATE 1-AbbVie trims full-year profit forecast on higher R&D expenses
...(Adds second quarter forecast in paragraph 5)
July 6 (Reuters......…
AbbVie trims full-year profit forecast due to higher R&D expenses
...(Reuters) - AbbVie Inc cut full-year profit forecast due......…
Form 8-K AbbVie Inc. For: Jul 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie to Host Second-Quarter 2023 Earnings Conference Call
NORTH CHICAGO, Ill., July 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2023 financial results on Thursday,…
AbbVie braces for increased Humira competition from cheaper ...
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
CollPlant reaches milestone in collagen agreement with AbbVie
The milestone triggers a $10 million payment to CollPlant, which is also collaborating with Stratasys on 3D-printed tissue....…
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer....…
This Is What Whales Are Betting On AbbVie
read more...…
Cheaper competition for Humira is hitting the market, but savings will depend on your insurance
Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the…
AbbVie president given added COO duties
AbbVie Inc. ABBV said late Thursday its vice chairman and president will take on the added role of chief operating…
Robert Michael named president and COO at AbbVie - filing
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K AbbVie Inc. For: Jun 29
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie, Genmab Announces Positive Results From Phase 1/2 Trial Of Epcoritamab
COPENHAGEN (dpa-AFX) - AbbVie (ABBV) and Genmab (GMAB) announced positive results from the follicular lymphoma or FL cohort of the…
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie....…
The Zacks Analyst Blog Highlights Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing
Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing are included in this Analyst Blog....…
AbbVie Announces Positive Results From Phase 1/2 Trial Of Epcoritamab In R/R Follicular Lymphoma
COPENHAGEN (dpa-AFX) - AbbVie (ABBV) and Genmab (GMAB) announced positive results from the follicular lymphoma or FL cohort of the…
AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment
AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment...…
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Company Announcement...…
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $134.95, moving -0.71% from the previous trading session....…
CollPlant nabs $10M milestone from AbbVie for dermal filler product
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval
AbbVie (ABBV) receives a positive recommendation from the European Unions medicinal products committee for the approval of its migraine treatment…
AbbVie: Weitere Anhebung der Dividende - Aktienanalyse
Kulmbach (www.aktiencheck.de) - AbbVie-Aktienanalyse von "Der Aktionär":
Michael Diertl vom Anlegermagazin "Der Aktionär" nimmt die Aktie des Pharmakonzerns AbbVie Inc. (ISIN:…
AbbVie: Dividende erhöht – Stimmt das Gesamtbild?
Wie auch die Aktien anderer Schwergewichte im Pharma- und Biotech-Sektor befindet sich AbbVie seit Jahresbeginn deutlich im Minus. Dennoch ließ…
AbbVie migraine therapy endorsed in Europe
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Gets Positive CHMP Opinion For Migraine Treatment
AbbVie Gets Positive CHMP Opinion For Migraine Treatment...…
AbbVie declares $1.48 dividend
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill., June 22, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a…
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what…
The Zacks Analyst Blog Highlights PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs
PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs are included in this Analyst Blog....…
Top Analyst Reports for PepsiCo, AbbVie & Honeywell
Todays Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), AbbVie Inc. (ABBV) and Honeywell…
UPDATE 1-Coherus resolves part of dispute with AbbVie over Humira biosimilar
... in paragraph 6)
June 15 (Reuters) - Coherus BioSciences said......…
AbbVie: Risankizumab Meets Endpoint In Phase 3 Maintenance Study In Ulcerative Colitis Patients
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AbbVie (ABBV) reported positive top-line results from COMMAND, Phase 3 maintenance study, showing risankizumab achieved the primary…